Diabetes Treatment
21 articles on Diabetes Treatment, written by Shotlee and medically reviewed for clinical accuracy.
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
5 min read
GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
6 min read
Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
5 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
Low-Cost Semaglutide Generics Coming to India as Patent Expires
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
5 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
Can GLP-1 Drugs Power Healthify's Coaching Future? Semaglutide Shift
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
5 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read
How GLP-1 Drugs May Lead to New Eating Disorders
As millions use GLP-1 medications like Ozempic for weight loss, clinicians are seeing a rise in new eating disorders dubbed 'agonorexia.' These drugs' powerful appetite suppression may drive dangerous food and body image obsessions, even in those without prior history. Experts warn current screening may miss at-risk patients.
6 min read
Generic Ozempic & Wegovy in India: Patient Guide
Generic versions of blockbuster GLP-1 drugs Ozempic and Wegovy are now approved in India, promising lower costs and wider access. Patients can expect semaglutide generics from Sun Pharma, Zydus Lifesciences, and others amid patent expiry in 2026. This guide breaks down the science, benefits, and key considerations for safe use.
4 min read
Canada-based pharmacy service to provide Indian-manufactured Ozempic to American consumers
A Canada-based online pharmacy service has started supplying Novo Nordisk's diabetes drug Ozempic, sourced from India, to US patients seeking affordable options. The pre-filled pens are available in various doses with a valid prescription and free shipping. This move responds to rising US drug prices and growing consumer interest in international pharmacy services.
2 min read
Eli Lilly's Mounjaro Included in China's State Health Insurance for Type 2 Diabetes Management
Eli Lilly's diabetes medication Mounjaro has been incorporated into China's government health insurance program effective from January 1, aimed at individuals with type 2 diabetes. This move boosts drug availability in a nation of 1.4 billion people, though it may lead to reduced pricing. Mounjaro, a weekly injection, became available in China earlier this year after Novo Nordisk's Ozempic was introduced in 2021.
2 min read
Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic
Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.
1 min read
Novo Nordisk India's Vikrant Shrotriya on Ensuring Ozempic Supply
Vikrant Shrotriya of Novo Nordisk India details Ozempic's launch in India, emphasizing stable supply and accessibility. He addresses patent expiry and competition, focusing on broader patient access and combating obesity.
6 min read
Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly
The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.
2 min read
Mounjaro by Eli Lilly Approved for China's State Insurance Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
2 min read
GLP-1 Breakthrough: Mazdutide Outperforms Semaglutide for Weight Loss & Diabetes
New research shows that Mazdutide may be superior to Semaglutide (Ozempic/Wegovy) for weight loss and improved blood sugar control. Learn about this exciting development and what it means for the future of diabetes and weight management.
3 min read